How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Skin Conditions in Diabetes Mellitus

Skin Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Skin (...) Conditions in Diabetes Mellitus Skin Conditions in Diabetes Mellitus Aka: Skin Conditions in Diabetes Mellitus , Diabetic Skin Disorders II. Associated Conditions: Diabetes Mellitus related See Xanthoma diabeticorum Xanthomas suggest Bullosis Diabeticorum (rare) e on extremities (especially feet) Usually heel without scarring Diabetic Ulcer Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Skin Conditions in Diabetes Mellitus." Click

2018 FP Notebook

2. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) the Fridericia formula R AC Accumulation ratio RH relative humidity RQ (Environmental) Risk Quotient SBP systolic blood pressure SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics TAMC total aerobic microbial count TYMC total combined yeasts/moulds count T2DM type 2 diabetes mellitus t max time to C max UGE urinary glucose excretion UGT uridine 5’-diphospho-glucuronosyltransferase ULN upper limit of normal UV ultraviolet UV-Vis ultraviolet

2018 European Medicines Agency - EPARs

3. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use (...) analysis plan SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics SMQ Standard MedDRA Query SOC System organ class T2DM type 2 diabetes mellitus TAMC total aerobic microbial count Tmax time to first occurrence of maximum observed concentration TYMC total combined yeasts/moulds count UGE urinary glucose excretion ULN upper limit of normal US United States USPI United States Prescribing Information UTI urinary tract infection UV ultraviolet

2018 European Medicines Agency - EPARs

4. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Steglujan on 25 January 2018. Assessment report EMA/86941/2018 Page 9/139 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition The indication as initially proposed for Steglujan is: “Steglujan, fixed-dose combination of ertugliflozin and sitagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve (...) Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products

2018 European Medicines Agency - EPARs

5. The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series

The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2018 Clinical Trials

6. Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin

Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 27 July 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment Continuous glucose monitoring (CGM real-time) and flash glucose (...) monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin Project ID: OTJA08 This report is part of the project / joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020) Continuous (real-time) and flash glucose monitoring as personal, standalone systems in patients with DM treated with insulin Version 1.4, 27 July 2018 EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date

2018 EUnetHTA

7. Adult Type 1 diabetes mellitus

| Adult type 1 diabetes mellitus | A National Clinical GuidelineNational Institute for Health and Clinical Excellence The UK’s National Institute for Health and Care Excellence (NICE) provides evidence-based guidance and advice to improve health and social care. NICE’s Centre for Guidelines develops guidance on the promotion of good health; the prevention of ill health; the appropriate treatment and care for people with specific diseases and conditions; social care and service delivery. The guidelines (...) Clinical Guideline | Adult type 1 diabetes mellitus 2 Development of the National Clinical Guideline 2.1 Background Type 1 diabetes is an autoimmune condition that causes destruction of the insulin producing cells in the pancreas. As a result of the loss of insulin production, people with type 1 diabetes must administer subcutaneous insulin in order to manage their blood glucose. Type 1 diabetes is a challenging condition to manage. Successful management of diabetes requires motivation, education

2018 National Clinical Guidelines (Ireland)

8. Granuloma annulare: relationship to diabetes mellitus, thyroid disorders and tuberculin skin test (PubMed)

Granuloma annulare: relationship to diabetes mellitus, thyroid disorders and tuberculin skin test Granuloma annulare is a benign inflammatory disease of the skin. The etiology and pathogenesis of the disease are not yet determined, but some authors have proposed that it might be associated with a variety of underlying conditions such as thyroid disorders, diabetes mellitus and positive tuberculin skin test.This study was conducted to find the probable relationship between granuloma annulare (...) and diabetes mellitus, thyroid disorders and positive tuberculin skin test.A total of 28 patients with granuloma annulare were recruited from our dermatology outpatient clinic, and data on sex, age and distribution of granuloma annulare lesions were collected. Forty-one age- and sex-matched apparently healthy volunteers serving as controls were also included. Thyroid stimulating hormone (TSH), fasting blood sugar (FBS) and tuberculin skin tests were performed for both groups.Mean serum level of FBS

Full Text available with Trip Pro

2017 Clinical, cosmetic and investigational dermatology

9. Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development (...) as these outputs are produced as required for our stakeholders. > > > Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus October 2017 The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving

2017 NIHR Innovation Observatory

10. Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus

2019 LY-900014 (ultra-rapid lispro) is in development for the treatment of adult patients with type 1 diabetes mellitus. Type 1 diabetes mellitus is a condition which usually starts early in life and occurs as a result of the pancreas not producing enough (or sometimes any) insulin. This results in elevated blood sugar levels which can damage many organs in the body. Type 1 diabetes usually runs in families. While type 1 diabetes cannot be cured, having regular, at least daily, injections (...) Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently

2017 NIHR Innovation Observatory

11. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2017 University of Michigan Health System

12. Management of Diabetes Mellitus in Primary Care

approach for setting individualized target goals based upon life expectancy, comorbid conditions, patient preferences, and absolute benefits and potential risks of therapy.[2] It also emphasized the risks of hypoglycemia. In 2010, the VA and DoD published a CPG for the Management of Diabetes Mellitus (2010 DM CPG), which was based on evidence reviewed through June 2009. Since the release of that guideline, a growing body of research has expanded the general knowledge and understanding of DM. Follow-up (...) Management of Diabetes Mellitus in Primary Care VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN PRIMARY CARE Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care

2017 VA/DoD Clinical Practice Guidelines

13. Sex Effects in High-impact Conditions for Women Veterans - Depression, Diabetes, and Chronic Pain

understand sex differences in intervention effects for high-impact medical conditions, and (3) identify gaps in evidence about the efficacy of interventions in women. Methods: We used a stakeholder-driven approach to identify high-priority conditions and interventions. From an initial list of 36 conditions, we used a forced-rank methodology to identify 3 conditions for evaluation: depressive disorders, type 2 diabetes mellitus, and chronic pain conditions (chronic low back pain [CLBP], chronic knee (...) Sex Effects in High-impact Conditions for Women Veterans - Depression, Diabetes, and Chronic Pain 4 Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Mapping the Evidence: Sex Effects in High-impact Conditions for Women Veterans – Depression, Diabetes, and Chronic Pain September 2015 Prepared for: Department of Veterans Affairs Veterans Health Administration Quality Enhancement Research Initiative Health Services Research

2016 Veterans Affairs Evidence-based Synthesis Program Reports

14. Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus

to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus: A Review of Guidelines DATE: 15 June 2015 CONTEXT AND POLICY ISSUES People with type 2 diabetes, also known as non-insulin-dependent diabetes (...) Diabetic Diets for Frail Elderly Long-Term Care Residents with Type II Diabetes Mellitus Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state - a systematic review. (PubMed)

Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state - a systematic review. Diabetes mellitus and the prediabetic state are associated with a number of skin manifestations. This study is a systematic review of the following manifestations: acanthosis nigricans (AN), skin tags (ST), diabetic dermopathy (DD), rubeosis faciei (RF), pruritus (PR), granuloma annulare (GA), necrobiosis lipoidica (NL), scleroedema diabeticorum (SD) and bullosis diabeticorum (BD (...) ). These conditions possibly relate to underlying diabetogenic mechanisms. Our aim was to determine whether skin signs are feasible as cutaneous markers for the prediabetic or diabetic state.Data were collected from the databases PubMed, Embase and Cochrane. Articles were excluded if the populations presented with comorbidities or received treatment with drugs affecting the skin. Also, animal studies, studies with poor methodology and pilot studies were excluded.Among the 34 included original articles

2016 Danish medical journal

16. Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

) or sitagliptin (SITA) at the dose of 100 mg/day (N = 36), as a single daily dose, for 12 weeks. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Evogliptin Drug: Sitagliptin Drug: Placebo Evogliptin Drug: Placebo Sitagliptin Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 146 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider (...) Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

17. Semaglutide (Ozempic) - Diabetes Mellitus

to all CHMP members on 28 November 2017. • During the meeting on 11-14 December 2017, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Ozempic on 14 December 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Type 2 Diabetes Mellitus (T2D) is a progressive chronic metabolic disease primarily characterised by abnormal glucose metabolism. Data (...) Semaglutide (Ozempic) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 14 December 2017 EMA/CHMP/715701/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ozempic International non

2018 European Medicines Agency - EPARs

18. Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone or diabetes medication naïve patient Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Gemigliptin 50mg Drug: Dapagliflozin 10mg Procedure: Diet/exercise questionnaire Device: Continuous Glucose Monitoring System(CGMS) Drug (...) : No Criteria Inclusion Criteria: Patients with type 2 diabetes mellitus of 20~70years of age at the time of Visit 1 (Screening) Patients with HbA1c measured in the local lab ranged from 7 to 11%satisfying the following conditions at the time of Visit 1(Screening) Type 2 diabetes mellitus medication naïve patients or patients who had not taken diabetes medication other than metformin within 8 weeks prior to Visit 1(Screening) For patients who have been taking metformin alone within 12 weeks prior to visit 1

2017 Clinical Trials

19. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence

time)Less biological (day-to-day) variability compared with single fasting or 2-h glucose , , Eliminates need for fasting or timed samplesUnaffected by acute illness or recent activity (eg, physical activity) Already used as a guide to adjust diabetes mellitus treatment Laboratory methods are well standardized in the US and some other countries More robust predictor of complications than fasting blood glucose , Certain conditions interfere with the interpretation of results , , ( ), including (...) , that is, hemoglobin characteristics (other than hemoglobinopathies), red cell turnover, and the tendency of hemoglobin to undergo glycation, may contribute to variability in the population. In summary, updated diagnostic criteria for diabetes mellitus are well aligned with the current evidence linking A 1c to long-term complications. Because the same tests identify diabetes mellitus and prediabetes, current guidelines represent a convenient approach to identifying individuals with either condition, so individuals

Full Text available with Trip Pro

2015 American Heart Association

20. Gestational diabetes mellitus

is established outside of pregnancy (before or after) *Pre-diabetes • A condition in which blood glucose levels are higher than normal but not high enough to be diagnostic of type 2 diabetes • Diagnosis is established outside of pregnancy (before or after) • Includes impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) *Management not discussed in this guideline Queensland Clinical Guideline: Gestational diabetes mellitus Refer to online version, destroy printed copies after use Page 11 (...) Test for microalbuminuria Queensland Clinical Guideline: Gestational diabetes mellitus Refer to online version, destroy printed copies after use Page 17 of 38 3.1 Maternal surveillance Table 11. Maternal surveillance Aspect Recommendation Monitoring • Women with GDM require increased surveillance throughout pregnancy o Maintain a high index of suspicion for associated conditions (e.g. preeclampsia) • Reassess the requirement for increased antenatal contact with multidisciplinary team members

2015 Queensland Health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>